Sharescart Research Club logo
Products
Research
Tools
About
  • Home
  • /
  • Marksans Pharma
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel

Marksans Pharma

WEBSITE BSE:524404 NSE: MARKSANS Inc. Year: 1992 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock

₹190.2 -2.8 | 1.5%

Last updated: 15:59

Consolidated Standalone

Last updated: 15:59

Marksans Pharma Overview

Marksans Pharma Ltd, collectively with its subsidiaries, engages within the research and development, production, advertising and marketing, distribution, and sale of generic pharmaceutical formulations in North America, Europe, the UK, Australia, New Zealand, and across the world. The agency offers products in the analgesic, anti inflammatory, benign prostatic hyperplasia, epilepsy, hyperparathyroidism, diabetic and antidiabetic, ache management, neurology, hormonal, antifungal, antiulcerative, cardiovascular, vitamin, cough and cold, dermatol...Read More

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Marksans Pharma Key Financials

Market Cap ₹8620 Cr.

Stock P/E 22.5

P/B 3.1

Current Price ₹190.2

Book Value ₹ 61.8

Face Value 1

52W High ₹270.6

Dividend Yield 0.42%

52W Low ₹ 156

Edit Ratio

Marksans Pharma Share Price

₹ | |

Volume
Price

Marksans Pharma Quarterly Price

Quarterly Monthly
Show Value Show %

Marksans Pharma Peer Comparison

Marksans Pharma Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 531 586 560 591 642 682 708 620 720 754
Other Income 19 5 17 15 -0 36 17 6 22 20
Total Income 550 591 577 606 642 718 725 626 742 775
Total Expenditure 417 453 450 462 495 551 583 520 576 594
Operating Profit 133 138 126 143 147 167 142 106 166 181
Interest 2 3 5 3 3 3 3 6 6 6
Depreciation 18 22 21 20 20 21 23 23 27 24
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 114 113 100 120 125 143 116 77 133 151
Provision for Tax 30 30 23 31 27 38 25 18 34 37
Profit After Tax 84 83 78 89 98 105 91 58 99 114
Adjustments -0 0 1 -0 -1 -1 -0 0 -1 -0
Profit After Adjustments 84 83 78 89 97 105 91 58 98 113
Adjusted Earnings Per Share 1.8 1.8 1.7 2 2.1 2.3 2 1.3 2.2 2.5

Marksans Pharma Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 797 893 767 913 1000 1134 1376 1491 1852 2177 2623 2802
Other Income 12 13 19 8 5 0 7 42 59 50 70 65
Total Income 809 906 786 921 1005 1135 1383 1533 1911 2228 2693 2868
Total Expenditure 621 761 734 834 868 942 1037 1232 1513 1719 2094 2273
Operating Profit 188 145 52 87 137 193 346 301 399 509 599 595
Interest 16 10 7 10 10 9 8 8 9 11 12 21
Depreciation 16 28 30 27 23 27 36 45 52 74 83 97
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 156 107 15 50 104 157 302 248 338 424 504 477
Provision for Tax 44 24 4 14 24 36 64 61 72 109 121 114
Profit After Tax 112 83 11 36 80 121 239 187 265 315 383 362
Adjustments -3 -4 -2 -3 -4 -4 -3 -2 1 -1 -2 -1
Profit After Adjustments 109 79 9 33 76 117 236 185 266 314 381 360
Adjusted Earnings Per Share 2.7 1.9 0.2 0.8 1.9 2.9 5.8 4.5 5.9 6.9 8.4 8

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 20% 21% 18% 13%
Operating Profit CAGR 18% 26% 25% 12%
PAT CAGR 22% 27% 26% 13%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -17% 34% 23% 15%
ROE Average 17% 17% 20% 20%
ROCE Average 23% 23% 26% 23%

Marksans Pharma Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 380 454 433 471 542 636 886 1202 1745 2065 2467
Minority's Interest 8 8 6 10 10 13 19 21 20 21 22
Borrowings 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 1 -2 16 16 17 24 24 57 84 205 273
Total Current Liabilities 286 259 296 235 233 229 299 380 341 390 477
Total Liabilities 676 720 752 731 802 902 1228 1660 2190 2681 3240
Fixed Assets 166 270 267 279 270 303 309 428 486 776 982
Other Non-Current Assets 1 10 1 1 1 6 16 7 29 43 54
Total Current Assets 509 440 484 451 531 594 903 1225 1675 1862 2204
Total Assets 676 720 752 731 802 902 1228 1660 2190 2681 3240

Marksans Pharma Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 47 185 35 25 40 34 94 112 206 382 403
Cash Flow from Operating Activities 155 31 14 50 27 233 179 99 237 230 207
Cash Flow from Investing Activities -33 -123 -21 -39 -13 -60 -45 -84 -259 -141 -49
Cash Flow from Financing Activities 17 -58 -3 3 -21 -114 -15 80 198 -69 -65
Net Cash Inflow / Outflow 138 -150 -10 15 -7 60 118 94 176 21 93
Closing Cash & Cash Equivalent 185 35 25 40 33 94 212 206 382 403 496

Marksans Pharma Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 2.67 1.92 0.22 0.8 1.87 2.86 5.76 4.51 5.88 6.92 8.4
CEPS(Rs) 3.13 2.71 1.01 1.53 2.52 3.6 6.71 5.66 7 8.59 10.28
DPS(Rs) 0.12 0.12 0.05 0.05 0.05 0.1 0.25 0.25 0.5 0.6 0.8
Book NAV/Share(Rs) 8.97 10.79 10.59 11.5 13.25 15.54 21.66 27.1 38.51 45.57 54.44
Core EBITDA Margin(%) 22.07 14.82 4.29 8.59 13.21 16.95 24.4 16.71 16.64 20.03 19.25
EBIT Margin(%) 21.58 13.1 2.83 6.58 11.4 14.63 22.28 16.53 17 18.99 18.77
Pre Tax Margin(%) 19.57 11.96 1.94 5.46 10.43 13.86 21.71 15.98 16.56 18.5 18.35
PAT Margin (%) 14.05 9.26 1.48 3.92 8.04 10.65 17.14 12.06 13.01 13.75 13.93
Cash Profit Margin (%) 16.08 12.41 5.4 6.86 10.32 13 19.74 14.95 15.55 17 16.97
ROA(%) 19.21 11.86 1.54 4.83 10.49 14.17 22.4 12.94 13.78 12.93 12.93
ROE(%) 45.15 20.45 2.59 7.92 15.88 20.49 31.33 18.72 18.59 16.53 16.89
ROCE(%) 44.64 23.16 4 10.6 18.51 25.57 39.76 23.82 22.89 22.4 22.5
Receivable days 80.88 81.87 110.59 84.88 64.51 67.57 67.57 78.56 72.63 69.35 65.99
Inventory Days 53.3 60.86 85.14 81.63 93.32 86.1 84.73 97.65 81.36 87.89 97.24
Payable days 77.93 80.92 111.69 83.59 67.39 69.55 85.57 93.88 85.31 87.7 91.59
PER(x) 23.07 24.09 218.39 39.33 13.3 4.86 8.67 10.1 11.99 21.89 26.48
Price/Book(x) 6.87 4.28 4.45 2.75 1.87 0.89 2.31 1.68 1.83 3.33 4.08
Dividend Yield(%) 0.19 0.26 0.11 0.16 0.2 0.72 0.5 0.55 0.71 0.4 0.36
EV/Net Sales(x) 3.06 2.19 2.63 1.5 1.08 0.44 1.35 1.04 1.36 2.86 3.58
EV/Core EBITDA(x) 12.97 13.48 38.91 15.81 7.92 2.57 5.35 5.18 6.32 12.23 15.68
Net Sales Growth(%) 26.46 12.13 -14.12 18.97 9.57 13.41 21.33 8.33 24.23 17.56 20.46
EBIT Growth(%) 62.9 -31.95 -81.47 176.93 89.88 45.59 86.93 -17.47 35.48 25.36 18.61
PAT Growth(%) 52.07 -26.1 -86.3 215.87 124.68 50.12 97.54 -21.68 42.02 18.68 21.51
EPS Growth(%) 43.22 -28.23 -88.74 272.77 132.11 53.05 101.63 -21.77 30.32 17.8 21.32
Debt/Equity(x) 0.23 0.19 0.25 0.25 0.18 0.03 0.02 0.04 0.02 0.01 0.01
Current Ratio(x) 1.78 1.7 1.63 1.92 2.28 2.59 3.02 3.22 4.91 4.78 4.62
Quick Ratio(x) 1.32 1.05 0.99 0.99 1.02 1.54 1.67 2.11 3.49 3.19 2.85
Interest Cover(x) 10.72 11.52 3.19 5.87 11.8 18.97 38.84 30.31 37.99 38.8 44.22
Total Debt/Mcap(x) 0.04 0.05 0.06 0.09 0.1 0.03 0.01 0.02 0.01 0 0

Marksans Pharma Shareholding Pattern

# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 43.85 43.85 43.87 43.87 43.87 43.87 43.87 43.87 43.87 43.87
FII 15.56 15.57 18.6 21.31 21.96 22.2 19.88 16.92 8.12 16.76
DII 4.76 5.17 3.75 4.1 4.3 4.56 5.5 5.28 5.91 6.57
Public 35.83 35.4 33.78 30.71 29.87 29.37 30.75 33.93 42.09 32.79
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Marksans Pharma News

Marksans Pharma Pros & Cons

Pros

  • Company has delivered good profit growth of 25% CAGR over last 5 years
  • Company is almost debt free.

Cons

  • Promoter holding is low: 43.87%.
  • Debtor days have increased from 87.7 to 91.59days.
  • Stock is trading at 3.1 times its book value.

* The pros and cons are machine generated.

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares
whatsapp

Please Login!

Click to Login
OR
Get free Account

Error!